Articles From: Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD334 for Autoimmune Diseases to Argentina Labor Ministry Starts Mediation Between Vale, Mine Workers


2013/4/5
SAN DIEGO , April 5, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of dosing in a Phase 1 clinical trial of APD334, a novel oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P 1 ) receptor for the potential treatment of autoimmune diseases.
Sign-up for Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD334 for Autoimmune Diseases investment picks
2013/5/2
-- Conference Call and Webcast Scheduled for Today at 5:15 p.m. Eastern Time --
Sign-up for Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2013 Financial Results investment picks
2013/3/4
-- Conference Call and Webcast Scheduled for Today at 8:30 a.m. Eastern Time --
Sign-up for Arena Pharmaceuticals Provides Corporate Update and Reviews Fourth Quarter and Full Year 2012 Financial Results investment picks
2013/5/7
-- Arena to Receive $65 Million in Milestone Payments from Eisai --
Sign-up for Arena Pharmaceuticals Provides Update on Upcoming US Launch of BELVIQ® (lorcaserin HCl) for Chronic Weight Management investment picks
2013/4/26
SAN DIEGO , April 26, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that it will provide a corporate update and discuss first quarter 2013 financial results after the NASDAQ Global Select Market closes on Thursday, May 2, 2013 .
Sign-up for Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, May 2 investment picks
2013/5/10
SAN DIEGO , May 10, 2013  /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15, 2013 , at 2:20 p.m. Pacific Time ( 5:20 p.m. Eastern Time ), at the Encore at the Wynn Las Vegas Hotel in Las Vegas, Nevada .
Sign-up for Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2013 Health Care Conference investment picks
2013/2/27
SAN DIEGO , Feb.
Sign-up for Arena Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference investment picks
2013/5/6
Ares Capital Corporation (Nasdaq: ARCC) announced today that its Board of Directors has promoted its President, Michael J.
Sign-up for Ares Capital Corporation Announces Management Promotions investment picks
2013/4/2
Ares Capital Corporation (Nasdaq: ARCC) announced that it plans to make a public offering of 16,650,000 shares of its common stock.
Sign-up for Ares Capital Corporation Announces Public Offering investment picks
2013/2/27
Ares Capital Corporation (“Ares Capital”) (NASDAQ: ARCC) announced that its Board of Directors has declared a first quarter dividend of $0.38 per share payable on March 29, 2013 to stockholders of record as of March 15, 2013.
Sign-up for Ares Capital Corporation Declares First Quarter 2013 Dividend of $0.38 Per Share and Announces December 31, 2012 Financial Results investment picks
2013/5/7
Ares Capital Corporation (“Ares Capital”) (NASDAQ: ARCC) announced that its Board of Directors has declared a second quarter dividend of $0.38 per share, payable on June 28, 2013 to stockholders of record as of June 14, 2013.
Sign-up for Ares Capital Corporation Declares Second Quarter 2013 Dividend of $0.38 Per Share and Announces March 31, 2013 Financial Results investment picks
2013/4/3
Ares Capital Corporation (Nasdaq: ARCC) announced that it has priced its public offering of 16,650,000 shares of its common stock.
Sign-up for Ares Capital Corporation Prices Public Offering investment picks
2013/4/9
Ares Capital Corporation (NASDAQ: ARCC) announced today that it will report earnings for the quarter ended March 31, 2013 on Tuesday, May 7, 2013.
Sign-up for Ares Capital Corporation Schedules Earnings Release for the Quarter Ended March 31, 2013 investment picks
2013/2/1
Ares Commercial Real Estate Corporation (NYSE: ACRE) (the “Company”) today announced the tax treatment for the Company's distributions on its common stock (CUSIP # 04013V-10-8) with respect to calendar year 2012 (excluding distributions made prior to the Company’s initial public offering): As the Company's aggregate distributions exceeded its earnings and profits, the January 2013 distribution declared in the fourth quarter of 2012 and payable to shareholders of record as of December 31, 2012 will be treated as a 2013 distribution for federal tax purposes.
Sign-up for Ares Commercial Real Estate Corporation Announces Tax Reporting Information for Calendar Year 2012 investment picks
2013/3/20
Ares Commercial Real Estate Corporation (NYSE: ACRE) announced today that it has entered into a transaction with a new sponsor group to facilitate the purchase of a Class B office building in Downtown Miami’s Brickell neighborhood that was collateralized by ACRE’s existing $47 million first mortgage loan.
Sign-up for Ares Commercial Real Estate Corporation Announces the Assumption of its Existing $47 Million Loan Commitment in Sale of Miami Office Property investment picks
2013/4/26
Ares Commercial Real Estate Corporation (NYSE: ACRE) announced today that it has appointed Brett White to its Board of Directors.
Sign-up for Ares Commercial Real Estate Corporation Appoints Former CEO of CBRE to its Board of Directors investment picks
2013/5/15
Ares Commercial Real Estate Corporation (NYSE: ACRE) announced today that its Board of Directors has appointed one of its directors, Todd Schuster, to join John Bartling, Jr., as Co-Chief Executive Officer of ACRE effective June 1, 2013.
Sign-up for Ares Commercial Real Estate Corporation Appoints Todd Schuster as Co-Chief Executive Officer investment picks
2013/3/14
Ares Commercial Real Estate Corporation (NYSE: ACRE) announced that it has declared a first quarter 2013 dividend of $0.25 per common share.
Sign-up for Ares Commercial Real Estate Corporation Declares First Quarter Dividend and Schedules Earnings Release for the Fiscal Year Ended December 31, 2012 investment picks
2013/5/15
Ares Commercial Real Estate Corporation (NYSE:ACRE) : MARCH 31, 2013 FINANCIAL RESULTS Ares Commercial Real Estate Corporation (NYSE:ACRE) announced that its Board of Directors has authorized a second quarter 2013 dividend of $0.25 per common share and announced its financial results for the quarter ended March 31, 2013.
Sign-up for Ares Commercial Real Estate Corporation Declares Second Quarter 2013 Dividend of $0.25 Per Common Share and Reports First Quarter 2013 Financial Results investment picks
2013/4/1
Ares Commercial Real Estate Corporation (NYSE: ACRE) announced earlier today that it led the closing of two new loan commitments totaling $132.6 million, including a $107.1 million first mortgage loan commitment collateralized by multi-family properties in Atlanta, Georgia and a $25.5 million first mortgage loan commitment collateralized by office properties in Kansas City, Missouri.
Sign-up for Ares Commercial Real Estate Corporation Leads Closing of Two Loan Commitments Totaling $132.6 Million investment picks
2013/5/3
Ares Commercial Real Estate Corporation (NYSE: ACRE) announced today that it closed a $15.0 million senior mortgage loan commitment collateralized by a 63,271 square foot office property located in Mountain View, CA, within the Silicon Valley market.
Sign-up for Ares Commercial Real Estate Corporation Originates Senior Loan for Silicon Valley Office Property investment picks
2013/4/1
Ares Commercial Real Estate Corporation (NYSE:ACRE) announced its financial results for the quarter and full-year ended December 31, 2012.
Sign-up for Ares Commercial Real Estate Corporation Reports Fourth Quarter and Full Year 2012 Financial Results investment picks
2013/5/8
Ares Commercial Real Estate Corporation (NYSE: ACRE) announced that it will report earnings for the quarter ended March 31, 2013 on Wednesday, May 15, 2013 and invites all interested persons to attend its webcast/conference call at 10:00 a.m. (Eastern Time) to discuss its first quarter 2013 financial results.
Sign-up for Ares Commercial Real Estate Corporation Schedules Earnings Release for the Quarter Ended March 31, 2013 investment picks
2013/5/15
Ares Commercial Real Estate Corporation (NYSE: ACRE) announced today that it has entered into a definitive agreement to acquire EF&A Funding, L.L.C, d/b/a Alliant Capital LLC from The Alliant Company, LLC and Alliant, Inc., for approximately $62.8 million through a combination of cash and stock.
Sign-up for Ares Commercial Real Estate Corporation To Acquire Alliant Capital LLC investment picks
2013/3/12
Ares Dynamic Credit Allocation Fund (NYSE: ARDC) announced the declaration of the monthly distribution of the Fund for the period ending March 31, 2013 of $0.117 per common share, payable as noted below.
Sign-up for Ares Dynamic Credit Allocation Fund Declares Monthly Distribution of $0.117 Per Share investment picks
2013/4/11
Ares Dynamic Credit Allocation Fund (NYSE: ARDC) announced the declaration of monthly distributions for the next three months of $0.117 per common share, payable as noted below.
Sign-up for Ares Dynamic Credit Allocation Fund Declares Monthly Distributions of $0.117 Per Share investment picks
2013/4/25
Areva SA (AREVA.FR) Thursday reiterated its full-year guidance as its revenue for the first quarter grew 12.5% to 2.28 billion ( $2.96 billion ) thanks to a strong performance of its back end and mining businesses.
Sign-up for Areva Reiterates Fiscal Year Guidance As 1Q Revenue Grows 12.5% investment picks
2013/4/18
French nuclear group Areva SA (AREVA.FR) Thursday said it signed a contract with U.S.-based utility Exelon Corp.
Sign-up for Areva Signs Nuclear Fuel Supplying Contract With U.S.' Exelon investment picks
2013/4/19
BUENOS AIRES --
Sign-up for Argentina Labor Ministry Starts Mediation Between Vale, Mine Workers investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD334 for Autoimmune Diseases to Argentina Labor Ministry Starts Mediation Between Vale, Mine Workers
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity